Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Mirador Capital Partners LP

Mirador Capital Partners LP increased its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 403.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,529 shares of the biotechnology company's stock after acquiring an additional 67,755 shares during the period. Mirador Capital Partners LP owned about 0.09% of Rocket Pharmaceuticals worth $1,063,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of RCKT. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Rocket Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,292 shares of the biotechnology company's stock worth $61,000 after acquiring an additional 582 shares in the last quarter. Values First Advisors Inc. purchased a new position in Rocket Pharmaceuticals in the third quarter valued at $108,000. SG Americas Securities LLC acquired a new position in Rocket Pharmaceuticals during the 3rd quarter worth $113,000. XTX Topco Ltd purchased a new stake in Rocket Pharmaceuticals during the 3rd quarter worth about $286,000. Finally, Verition Fund Management LLC acquired a new stake in Rocket Pharmaceuticals in the 3rd quarter valued at about $290,000. 98.39% of the stock is currently owned by hedge funds and other institutional investors.

Rocket Pharmaceuticals Stock Performance

NASDAQ:RCKT traded down $0.67 during mid-day trading on Thursday, reaching $10.21. 1,907,894 shares of the stock were exchanged, compared to its average volume of 1,707,659. The stock has a market capitalization of $930.71 million, a P/E ratio of -3.71 and a beta of 1.01. Rocket Pharmaceuticals, Inc. has a 1 year low of $10.12 and a 1 year high of $31.47. The company has a 50 day simple moving average of $13.10 and a 200-day simple moving average of $17.26. The company has a quick ratio of 6.05, a current ratio of 6.05 and a debt-to-equity ratio of 0.06.

Insider Transactions at Rocket Pharmaceuticals

In related news, CEO Gaurav Shah sold 11,091 shares of the stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $13.05, for a total transaction of $144,737.55. Following the completion of the sale, the chief executive officer now owns 707,328 shares in the company, valued at $9,230,630.40. This represents a 1.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders have sold 13,490 shares of company stock worth $176,045. Insiders own 28.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on RCKT shares. Jefferies Financial Group started coverage on Rocket Pharmaceuticals in a research report on Wednesday, December 18th. They set a "buy" rating and a $29.00 price objective for the company. Needham & Company LLC reiterated a "buy" rating and issued a $52.00 price target on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. Wedbush started coverage on shares of Rocket Pharmaceuticals in a research report on Monday, December 30th. They issued an "outperform" rating and a $32.00 price objective on the stock. Leerink Partners decreased their price objective on shares of Rocket Pharmaceuticals from $46.00 to $44.00 and set an "outperform" rating for the company in a research report on Tuesday, November 19th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 target price on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $47.27.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.